Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease | MicrobiomeTrials← Back to trialsNCT05493761
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
CompletedPHASE4INTERVENTIONAL
Trial Details
Start: 2022-12-23Est. Completion: 2026-07-16
Enrollment target: 72 participants Locations- Department of Endocrinology, "Hippokration" General Hospital of Thessaloniki, Thessaloniki, Greece
- 1st Department of Obstetrics and Gynecology, School, of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
- 424 General Military Hospital, Thessaloniki, Greece
Other microbiome trials you might be interested in
Non-alcoholic Fatty Liver Disease
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis…
Chandler, United StatesEst. completion Mar 29, 2028
Non-Alcoholic Fatty Liver DiseaseObesity
This will be a 6-month randomized clinical trial with two arms: moderately carbohydrate-restricted diet and a fat-restri…
Birmingham, United StatesCompleted Jul 21, 2026
Phase 3
Recruiting
Non-alcoholic Fatty Liver Disease
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH …
Arcadia, United StatesEst. completion Mar 24, 2028